Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
Kevin A. Hay(Occupational Cancer Research Centre), Cameron J. Turtle(The University of Sydney)
Cited by 1,099
Related Papers
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
|Blood|2016|743
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
|Nature Biotechnology|2017|623
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
|Blood|2017|564
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
|Blood|2019|399
Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs
|Journal for ImmunoTherapy of Cancer|2025|1